Literature DB >> 26079072

Ulcerative colitis-associated hospitalization costs: a population-based study.

Stephanie Coward, Steven J Heitman, Fiona Clement, James Hubbard, Marie-Claude Proulx, Scott Zimmer, Remo Panaccione, Cynthia Seow, Yvette Leung, Indraneel Datta, Subrata Ghosh, Robert P Myers, Mark Swain, Gilaad G Kaplan.   

Abstract

BACKGROUND: Hospitalization costs for ulcerative colitis (UC) following the introduction of infliximab have not been evaluated.
OBJECTIVE: To study predictors of costs for UC patients who were hospitalized for a flare or colectomy.
METHODS: Population-based surveillance identified adults (≥18 years of age) admitted to hospital for UC flare or colectomy between 2001 and 2009 in the Calgary Health Zone (Alberta). Medical charts were reviewed and patients stratified into three admission types: responsive to inpatient medical therapy (n=307); emergent colectomy (n=227); and elective colectomy (n=208). The annual median cost with interquartile range (IQR) was calculated. Linear regression determined the effect of admission type on hospital charges after adjusting for age, sex, smoking, comorbidities, disease extent, medication use (eg, infliximab) and year. The adjusted cost increase was presented as the percent increase with 95% CIs. Joinpoint analysis assessed for an inflection point in hospital cost after the introduction of infliximab.
RESULTS: Median hospitalization cost for UC flare, emergent colectomy and elective colectomy, respectively, were: $5,499 (IQR $3,374 to $8,904), $23,698 (IQR $17,981 to $32,385) and $14,316 (IQR $11,932 to $18,331). Adjusted hospitalization costs increased approximately 6.0% annually (95% CI 4.5% to 7.5%). Adjusted costs were higher for patients who underwent an elective colectomy (percent increase cost 179.8% [95% CI 151.6% to 211.1%]) or an emergent colectomy (percent increase cost 211.1% [95% CI 183.2% to 241.6%]) than medically responsive patients. Infliximab in hospital was an independent predictor of increased costs (percent increase cost 69.5% [95% CI 49.2% to 92.5%]). No inflection points were identified.
CONCLUSION: Hospitalization costs for UC increased due to colectomy and infliximab.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26079072      PMCID: PMC4610645          DOI: 10.1155/2015/627370

Source DB:  PubMed          Journal:  Can J Gastroenterol Hepatol        ISSN: 2291-2789


  22 in total

1.  Postoperative complications following colectomy for ulcerative colitis in children.

Authors:  Ing Shian Soon; Iwona Wrobel; Jennifer C C deBruyn; Reg Sauve; David L Sigalet; Belle S Kaplan; Marie-Claude Proulx; Gilaad G Kaplan
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-06       Impact factor: 2.839

Review 2.  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review.

Authors:  Natalie A Molodecky; Ing Shian Soon; Doreen M Rabi; William A Ghali; Mollie Ferris; Greg Chernoff; Eric I Benchimol; Remo Panaccione; Subrata Ghosh; Herman W Barkema; Gilaad G Kaplan
Journal:  Gastroenterology       Date:  2011-10-14       Impact factor: 22.682

3.  Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis.

Authors:  Gilaad G Kaplan; Ellen P McCarthy; John Z Ayanian; Joshua Korzenik; Richard Hodin; Bruce E Sands
Journal:  Gastroenterology       Date:  2008-01-10       Impact factor: 22.682

4.  Risk of comorbidities on postoperative outcomes in patients with inflammatory bowel disease.

Authors:  Gilaad G Kaplan; James Hubbard; Remo Panaccione; Abdel Aziz M Shaheen; Hude Quan; Geoffrey C Nguyen; Elijah Dixon; Subrata Ghosh; Robert P Myers
Journal:  Arch Surg       Date:  2011-08

5.  Direct medical cost of managing IBD patients: a Canadian population-based study.

Authors:  Charles N Bernstein; Teresa Longobardi; Greg Finlayson; James F Blanchard
Journal:  Inflamm Bowel Dis       Date:  2011-11-22       Impact factor: 5.325

Review 6.  Challenges associated with identifying the environmental determinants of the inflammatory bowel diseases.

Authors:  Natalie A Molodecky; Remo Panaccione; Subrata Ghosh; Herman W Barkema; Gilaad G Kaplan
Journal:  Inflamm Bowel Dis       Date:  2010-11-28       Impact factor: 5.325

7.  Postoperative complications and mortality following colectomy for ulcerative colitis.

Authors:  Shanika de Silva; Christopher Ma; Marie-Claude Proulx; Marcelo Crespin; Belle S Kaplan; James Hubbard; Martin Prusinkiewicz; Andrew Fong; Remo Panaccione; Subrata Ghosh; Paul L Beck; Anthony Maclean; Donald Buie; Gilaad G Kaplan
Journal:  Clin Gastroenterol Hepatol       Date:  2011-07-30       Impact factor: 11.382

8.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

Authors:  Gunnar Järnerot; Erik Hertervig; Ingalill Friis-Liby; Lars Blomquist; Per Karlén; Christer Grännö; Mogens Vilien; Magnus Ström; Ake Danielsson; Hans Verbaan; Per M Hellström; Anders Magnuson; Bengt Curman
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

9.  Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.

Authors:  Michael D Kappelman; Sheryl L Rifas-Shiman; Carol Q Porter; Daniel A Ollendorf; Robert S Sandler; Joseph A Galanko; Jonathan A Finkelstein
Journal:  Gastroenterology       Date:  2008-09-17       Impact factor: 22.682

10.  The impact of delays to admission from the emergency department on inpatient outcomes.

Authors:  Qing Huang; Amardeep Thind; Jonathan F Dreyer; Gregory S Zaric
Journal:  BMC Emerg Med       Date:  2010-07-09
View more
  10 in total

1.  Obesity Is Associated with Increased Risk of Colectomy in Inflammatory Bowel Disease Patients Hospitalized with Clostridium difficile Infection.

Authors:  Manish P Shrestha; Sasha Taleban
Journal:  Dig Dis Sci       Date:  2018-12-19       Impact factor: 3.199

2.  Serological, genetic and clinical associations with increased health-care resource utilization in inflammatory bowel disease.

Authors:  Phillip Gu; Anshika Kapur; Dalin Li; Talin Haritunians; Eric Vasiliauskas; David Q Shih; Stephan R Targan; Brennan Mr Spiegel; Dermot Pb Mcgovern; Jeanne T Black; Gil Y Melmed
Journal:  J Dig Dis       Date:  2018-01       Impact factor: 2.325

3.  Analysis of Healthcare Resource Utilization and Costs after the Initiation of Biologic Treatment in Patients with Ulcerative Colitis and Crohn's Disease.

Authors:  Sue Perera; Shibing Yang; Marni Stott-Miller; Joanne Brady
Journal:  J Health Econ Outcomes Res       Date:  2018-09-01

4.  A Microsimulation Model to Project the 5-Year Impact of Using Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Acute Flares.

Authors:  Parambir S Dulai; Vipul Jairath
Journal:  Dig Dis Sci       Date:  2020-11-13       Impact factor: 3.487

5.  The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.

Authors:  M Ellen Kuenzig; Eric I Benchimol; Lawrence Lee; Laura E Targownik; Harminder Singh; Gilaad G Kaplan; Charles N Bernstein; Alain Bitton; Geoffrey C Nguyen; Kate Lee; Jane Cooke-Lauder; Sanjay K Murthy
Journal:  J Can Assoc Gastroenterol       Date:  2018-11-02

6.  Ulcerative colitis: Impact of early disease clearance on long-term outcomes - A multicenter cohort study.

Authors:  Ferdinando D'Amico; Gionata Fiorino; Virginia Solitano; Eugenia Massarini; Lucas Guillo; Mariangela Allocca; Federica Furfaro; Alessandra Zilli; Stefanos Bonovas; Fernando Magro; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  United European Gastroenterol J       Date:  2022-09-15       Impact factor: 6.866

7.  Improved Healthcare Access Reduces Requirements for Surgery in Indigent IBD Patients Using Biologic Therapy: A 'Safety-Net' Hospital Experience.

Authors:  Phillip Gu; Eric Clifford; Andrew Gilman; Christopher Chang; Elizabeth Moss; David I Fudman; Phillip Kilgore; Urska Cvek; Marjan Trutschl; J Steven Alexander; Ezra Burstein; Moheb Boktor
Journal:  Pathophysiology       Date:  2022-07-18

8.  Role of Hospital Teaching Status on Outcomes of Patients with Inflammatory Bowel Disease: A Nationwide Analysis.

Authors:  Sachit Sharma; Simcha Weissman; Tej I Mehta; Muhammad Aziz; Ashu Acharya; Ishaan Vohra; Zubair Khan; Ahmad Khan; Ali Nawras; Michael Sciarra; Arun Swaminath
Journal:  Dig Dis Sci       Date:  2020-07-21       Impact factor: 3.487

9.  Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis.

Authors:  Matthew J Brookes; John Waller; Joseph C Cappelleri; Irene Modesto; Marco D DiBonaventura; Natalie Bohm; Ruth Mokgokong; Olivia Massey; Robert Wood; Danielle Bargo
Journal:  BMJ Open Gastroenterol       Date:  2020-09

10.  Hospitalizations and in-hospital mortality for inflammatory bowel disease in Brazil.

Authors:  Ana Luiza Vilar Guedes; Amanda Lopes Lorentz; Larissa Fernandes de Almeida Rios Rios; Beatriz Camara Freitas; Adriano Gutemberg Neves Dias; Ana Luísa Eckhard Uhlein; Felipe Oliveira Vieira Neto; Jobson Felipe Soares Jesus; Túlio de Sá Novaes Torres; Raquel Rocha; Vitor D Andrade; Genoile Oliveira Santana
Journal:  World J Gastrointest Pharmacol Ther       Date:  2022-01-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.